Novel therapeutic agents for systemic lupus erythematosus

被引：39

作者：

Gescuk, BD ^{[1
]}

Davis, JC ^{[1
]}

机构：

[1] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2002年 / 14卷 / 05期

关键词：

D O I：

10.1097/00002281-200209000-00006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis. Recent advances in immunology, oncology, and endocrinology have resulted in many potential therapies for SLE. These therapies include new immunosuppressants, biologic medications, tolerizing agents, immunoablation techniques, and hormonal medications. Each of these approaches will be discussed in this review. Some therapies are currently in use in clinical rheumatology practice (mycophenolate mofetil) and others are entering phase I trials (anti-BLyS monoclonal antibody). While some of these new therapies target specific inflammatory mechanisms in SLE (anti-CD40L monoclonal antibody), others work by nonspecific inhibition of the immune system (immunoablation). (C) 2002 Lippincott Williams Wilkins, Inc.

引用

页码：515 / 521

页数：7

共 63 条

[1] CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris [J].

Abrams, JR ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Goldfarb, MT ;

Goffe, BS ;

Menter, A ;

Lowe, NJ ;

Krueger, G ;

Brown, MJ ;

Weiner, RS ;

Birkhofer, MJ ;

Warner, GL ;

Berry, KK ;

Linsley, PS ;

Krueger, JG ;

Ochs, HD ;

Kelley, SL ;

Kang, SW .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1243-1252

[2] Mycophenolate mofetil and its mechanisms of action [J].

Allison, AC ;

Eugui, EM .

IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :85-118

[3]

Barthel HR, 2001, ARTHRIT RHEUM-ARTHR, V45, P472, DOI 10.1002/1529-0131(200110)45:5<472::AID-ART368>3.0.CO

[4]

2-O

[5] Tacrolimus clinical studies for atopic dermatitis and other conditions [J].

Bergman, J ;

Rico, MJ .

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2001, 20 (04) :250-259

[6] Successful mycophenolate mofetil treatment of glomerular disease [J].

Briggs, WA ;

Choi, MJ ;

Scheel, PJ .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (02) :213-217

[7] Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease [J].

Brodsky, RA ;

Petri, M ;

Smith, BD ;

Seifter, EJ ;

Spivak, JL ;

Styler, M ;

Dang, CV ;

Brodsky, I ;

Jones, RJ .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1031-1035

[8] Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation [J].

Burt, RK ;

Traynor, AE ;

Pope, R ;

Schroeder, J ;

Cohen, B ;

Karlin, KH ;

Lobeck, L ;

Goolsby, C ;

Rowlings, P ;

Davis, FA ;

Stefoski, D ;

Terry, C ;

Keever-Taylor, C ;

Rosen, S ;

Vesole, D ;

Fishman, M ;

Brush, M ;

Mujias, S ;

Villa, M ;

Burns, WH .

BLOOD, 1998, 92 (10) :3505-3514

[9] Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis [J].

Chan, TM ;

Li, FK ;

Tang, CSO ;

Wong, RWS ;

Fang, GX ;

Ji, YL ;

Lau, CS ;

Wong, AKM ;

Tong, MKL ;

Chan, KW ;

Lai, KN .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1156-1162

[10]

Cohen S, 2001, ARTHRITIS RHEUM-US, V44, P1984, DOI 10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO

← 1 2 3 4 5 6 7 →